Novartis Korea said Friday that the Ministry of Food and Drug Safety has approved Piqray (ingredient: alpelisib) for treating menopausal patients with advanced breast cancer through combined use with fulvestrant.The drug can be prescribed to menopausal women with breast cancer whose tumors have PIK3
Symbenda (ingredient: bendamustine), a treatment for blood cancer, is expected to become unavailable in Korea within this year, but generic drugs are expected to replace the original medicine, industry officials said.Eisai Korea reportedly notified the Ministry of Food and Drug Safety in April that
China-based BeiGene has successfully developed poly (ADP-ribose) polymerase (PARP) inhibitor pamiparib for patients with advanced ovarian cancer, closely trailing multinational pharmaceuticals in the race for innovative medicine development.The new drug came after BeiGene developed two novel drugs -
Hanmi Pharmaceutical said that the U.S. Food and Drug Administration has granted the orphan drug designation to its LAPS Triple Agonist (HM15211) for treating idiopathic pulmonary fibrosis (IPF).The company has won 17 orphan drug designations – nine from the U.S. FDA, five from the European Medicine
SK Biopharmaceuticals registered sales of 140 billion won ($126 million), and an operating profit of 75.9 billion won in the first quarter.The company said Wednesday that the sales increase of its antiepileptic drug Xcopri (ingredient: cenobamate) in the U.S. and the first milestone payment of $110
A research team of the Institute for Basic Science (IBS) said Tuesday that deficiency in protein TANC2, which plays a crucial role in neuronal development, induces autism and impairs brain development. The research team, led by Professor Kim Eun-joon of the Synaptic Brain Dysfunctions Lab at the Kor
The Ministry of Food and Drug Safety has suspended the making and selling of six drugs commissioned by other drugmakers to HanAll Biopharma after confirming data manipulation.The ministry also started its procedure to revoke the item permission of the six products -- Samsung Itraconazole Tab., Spodi
HLB Pharmaceutical said Tuesday that its first-line therapy for liver cancer, rivoceranib, has significantly extended the overall survival period in the second phase 3 clinical trials performed in China.The company conducted the studies at 31 hospitals in China with 400 patients. It confirmed rivoce
While the global headquarters of Pfizer is giving its Covid-19 vaccine to its staff and their families for free, Pfizer Korea is rethinking whether to follow suit, industry sources said.In Korea, public concerns are growing over the shortage of Covid-19 vaccines.Industry watchers speculate that the
Handok Pharmaceuticals and CMG Pharmaceutical have agreed to transfer the technology of anticancer drug CHC2014, which targets Pan-TRK inhibitor in solid tumors, to Singapore’s AUM Biosciences for 193.4 billion won ($173 million).The two companies will grant rights to AUM Biosciences to develop, man
Celltrion Healthcare said the company has started global sales of Regkirona, its COVID-19 antibody treatment, by signing an export contract with Pakistan.Celltrion Healthcare signed a deal with the WAH Industries, Pakistan state-owned enterprise, to supply 100,000 vials of Regkirona as per a pre-agr
GSK has confirmed the efficacy of Trelegy Ellipta (ingredient: fluticasone furoate, umeclidinium, vilanterol) for treating patients with chronic obstructive pulmonary disease (COPD) in phase 4 clinical studies.The company said its new drug would be effective on COPD patients who could not control th
AstraZeneca’s Imfinzi, PD-L1 inhibiting immunotherapy, extended overall survival of non-small cell lung cancer (NSCLC) patients when used together with tremelimumab, an anti-CTLA4 antibody, and standard chemotherapy in the first-line treatment.However, questions remain whether the three-combination
Most of the biopharmaceutical companies that went public this year are maintaining their share prices at levels higher than their offering prices, according to market watchers.Seven biopharma firms made an initial public offering this year.The share prices of five -- SK Bioscience, Biodyne, NeoImmun
Daewoong Pharmaceutical said Thursday that it has completed the phase 1 clinical trial of the first-in-class Prolyl tRNA Synthetase (PRS) inhibitor for pulmonary fibrosis patients who lack therapeutic options and will soon enter the next phase.Park Joon-seok, head of Daewoong’s drug discovery center
The National Tax Service (NTS) and the Seoul Regional Tax Office have investigated the “inflated costs” of imported drugs by multinational pharmaceutical companies’ local offshoots since the last yearend, industry sources said on Friday.According to audit reports submitted to the Financial Superviso
Genexine said Thursday that it has recorded sales of 33 billion won ($29.3 million) operating profit of 13.1 billion won, and a net profit of 21.3 billion won in the first quarter thanks to its Covid-19 drug technology transfer.The sales in the first quarter increased by 328 percent from 7.7 billion
Novo Nordisk said Thursday that Xultophy (ingredient: insulin degludec, liraglutide), its fixed ratio drug for treating type 2 diabetes, began receiving health insurance coverage from Saturday.Xultophy has shown excellent hypoglycemic effect compared to the control group in DUAL clinical trials and
Korean pharmaceutical companies showed sluggish performances in the first quarter of this year as the protracted Covid-19 pandemic caused the contraction of the prescription market, analysts said.Despite stagnant sales and operating profits, some large companies managed to improve their bottom lines
Daewoong Pharmaceutical will resume the sales of its botulinum toxin (BTX) product, Nabota, in America, as the U.S. International Trade Commission (ITC) withdrew its import ban on Tuesday.The decision came after Medytox had requested the ITC to withdraw its order as part of the three-party settlemen